Bengaluru: A story of resilience, sacrifice, and hope unfolded recently at Aster RV Hospital, where 12-year-old Shreemantha ...

A man was living off just two portions of soup a week before he passed out and crashed into a van, causing about $30,000 of ...

A decision to forgo seizure medication and start using weight-loss remedies, which included living off two portions of soup ...

A decision to forgo seizure medication and start using weight-loss remedies, which included living off two portions of soup per week, has cost a man almost $16,000 after he passed out and crashed into ...

(1) The total number of outstanding shares of the Company on 24 January 2025 mentioned in the relevant transparency notifications amounts to 52,416,601, each share giving right to one (1) vote (being ...

Inc. today provided full-year Abecma® (idecabtagene vicleucel; ide-cel) sales results for 2024, in partnership with Bristol Myers Squibb (BMS). "We are pleased to see Abecma expansion in the third ...

ACLF clinical trials expected to initiate in 1Q253 clinical data readouts expected by year-end 2025 across the ACLF pipeline, including on-going UNVEIL-IT® Phase 2 trialData of on-going Phase 1b ...

As noted above, stellate cell activation is the central event in hepatic fibrosis. Activation consists of 2 major phases: (1) initiation (also called apreinflammatory stage) and (2) perpetuation ...

Hepatic fibrosis is a reversible wound healing response characterized by accumulation of extracellular matrix (ECM), or "scar," that follows chronic but not self-limited liver disease. The ECM ...

Transparency Notifications from Shareholders Ghent, Belgium - 3 February 2025 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of ...